Oppenheimer analyst Hartaj Singh maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX) today. The company’s shares closed yesterday at $147.59.
According to TipRanks.com, Singh is a 4-star analyst with an average return of 11.3% and a 42.6% success rate. Singh covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Syndax Pharmaceuticals Inc, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Vertex Pharmaceuticals is a Strong Buy with an average price target of $186.11.
See today’s analyst top recommended stocks >>
Vertex Pharmaceuticals’ market cap is currently $37.62B and has a P/E ratio of 171.62. The company has a Price to Book ratio of 15.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington’s disease and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
